Oxytocin May be Superior to Gliptins as a Potential Treatment for Diabetic COVID-19 Patients
Diabetes is a comorbidity associated with an increased risk of severe COVID-19. Gliptins are anti-diabetic drugs that inhibit dipeptidyl peptidase-4 (DPP4) and they have been proposed as a possible treatment for COVID-19 patients with and without diabetes due to their immunomodulatory properties. Ox...
Main Author: | Phuoc-Tan Diep |
---|---|
Format: | Article |
Language: | English |
Published: |
Ital Publication
2021-01-01
|
Series: | SciMedicine Journal |
Subjects: | |
Online Access: | https://www.scimedjournal.org/index.php/SMJ/article/view/181 |
Similar Items
-
Choosing a Gliptin
by: Vishal Gupta, et al.
Published: (2011-01-01) -
Acute pancreatitis with gliptins: Is it a clinical reality?
by: Muthukrishnan Jayaraman, et al.
Published: (2013-01-01) -
Vildagliptin: the first innovative DDP-4 inhibitor
by: Edvin Villkhauer
Published: (2010-09-01) -
Association between Dipeptidyl Peptidase-4 Inhibitors and Allergic Rhinitis in Asian Patients with Diabetes
by: Hsin-Hung Chen, et al.
Published: (2019-04-01) -
The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)